## Ovarian Cancer Chemotherapy **Key Point:** Paclitaxel + carboplatin is the gold-standard first-line regimen for epithelial ovarian cancer post-surgery, established by GOG and ICON trials. ### Why Paclitaxel + Carboplatin: - Synergistic activity: paclitaxel (microtubule stabilizer) + carboplatin (platinum alkylating agent) - Superior response rates and overall survival vs. single agents - Better tolerability than cisplatin-based regimens - Standard 6 cycles administered intravenously - Can be combined with bevacizumab (anti-VEGF) in advanced/recurrent disease ### Landmark Evidence: | Trial | Regimen | Outcome | |-------|---------|----------| | GOG-111 | Paclitaxel + Cisplatin | Improved OS vs. Cisplatin alone | | ICON3 | Paclitaxel + Carboplatin | Non-inferior to Paclitaxel + Cisplatin | | GOG-218 | Paclitaxel + Carboplatin ± Bevacizumab | Bevacizumab improves PFS | **Clinical Pearl:** Carboplatin is preferred over cisplatin in most patients due to better renal tolerance and lower neurotoxicity, though cisplatin may be used in selected fit patients.
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.